Medifast (MED) Common Equity (2010 - 2026)

Medifast's Common Equity history runs 17 years deep, the most recent figure standing at $197.7 million for Q1 2026.

• Quarterly Common Equity fell 6.29% year-over-year to $197.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.7 million (down 6.29% YoY) and the FY2025 annual result came in at $198.9 million, down 5.33% from the prior year.
• Common Equity was $197.7 million for Q1 2026 at Medifast, down from $198.9 million in the prior quarter.
• Across five years, Common Equity topped out at $216.0 million in Q1 2022 and bottomed at $129.5 million in Q2 2022.
• A 5-year average of $192.6 million and a median of $201.5 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity plunged 33.5% — and 2023, when it soared 43.32%.
• Medifast's Common Equity stood at $155.0 million in 2022, then gained by 29.95% to $201.5 million in 2023, then advanced by 4.28% to $210.1 million in 2024, then fell by 5.33% to $198.9 million in 2025, then fell by 0.62% to $197.7 million in 2026.
• Business Quant data shows MED's Common Equity at $197.7 million in Q1 2026, $198.9 million in Q4 2025, and $214.7 million in Q3 2025.